AZA significantly decreased human T-cell proliferation as well as IFN-γ and TNF-α serum levels, and it reduced the expression of GRANZYME B and PERFORIN 1 by cytotoxic T cells, leading to prevention of GVHD without compromising GVL effects. Here, TNF is linked to graft versus host disease.